RESEARCH PAPER

Taylor & Francis

OPEN ACCESS Check for updates

Utility of novel 2-furanones in synthesis of other heterocyclic compounds having anti-inflammatory activity with dual COX2/LOX inhibition

Rania H. Abd El-Hameed^a, Shahenda Mahgoub^b, Hend M. El-Shanbaky^a, Mosaad S. Mohamed^a and Sahar A. Ali^b

^aPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Cairo, Egypt; ^bDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Helwan University, Cairo, Egypt

ABSTRACT

Inflammation is associated with the development of several diseases comprising cancer and cardiovascular disease. Agents that suppress cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, besides chemokines have been suggested to minimise inflammation. Here, a variety of novel heterocyclic and non-heterocyclic compounds were prepared from novel three furanone derivatives. The structures of all synthesised compounds were confirmed by elemental and spectral analysis including mass, IR, and ¹H-NMR spectroscopy. Anti-inflammatory activities of these synthesised compounds were examined *in vitro* against COX enzymes, 15-LOX, and tumour necrosis factor- α (TNF- α), using inhibition screening assays. The majority of these derivatives showed significant to high activities, with three pyridazinone derivatives (**5b**, **8b**, and **8c**) being the most promising anti-inflammatory agents with dual COX-2/15-LOX inhibition activities along with high TNF- α inhibition activity.

ARTICLE HISTORY

Received 8 January 2021 Revised 7 February 2021 Accepted 18 March 2021

KEYWORDS

Pyridazinone; selective COX-2 inhibitor; 15-LOX inhibitors; TNF-α inhibitor; anti-inflammatory

1. Introduction

Inflammation is a protective physiological defence mechanism provided by the body immune system in response to toxins, infectious pathogens, and local injury¹. It occurs as a result of biosynthesis of pro-inflammatory mediators (leukotrienes [LTs] and prostaglandins [PGs]) from arachidonic acid (AA) by the action of the enzymes lipoxygenase (LOX) and cyclooxygenase (COX), respectively. Although inflammation is a normal defence mechanism, persistent/untreated inflammation leads to complicated events with release of many mediators that can turn the condition to be harmful and may lead to the development of certain diseases, as asthma, rheumatoid arthritis, atherosclerosis, diabetes, and cancer². Therefore, anti-inflammatory agents may be helpful in the management of inflammatory disorders³. Anti-inflammatory effects of various compounds may result mainly from their ability to inhibit some of the key enzymes involved in inflammation and/ or cell signalling pathways such as COX and LOX⁴.

Thus, inhibition of these enzymes may be valuable treatment for inflammatory conditions. In the human system, COX occurs in two isoforms: COX-1 and COX-2⁵. Both isoforms catalyse a COX reaction in which they act on AA as substrate. COX isoforms are haem containing enzymes that demonstrate distinctive expression profiles and roles in numerous physiological processes.⁶ COX-1 is constitutive isoform and is found in the gastrointestinal (GI)-tract, renal collecting tubules, and platelets and is believed to be responsible for the maintenance of physiological homeostasis such as renal function and GI integrity through production of gastroprotective PGs. On the other hand, the inducible isoform; COX-2 is released during tissue injury and induced by many kinds of inflammatory mediators; playing an important role in the proinflammatory PGs biosynthesis 7 .

Inhibition of both isoforms of COX by classical nonsteroidal anti-inflammatory drugs (NSAIDs) leads to inhibition of gastroprotective PGs produced *via* the COX-1 pathway; which occurs along with suppression of the pathological COX effects; resulting in the GI toxicities accompanying the use of numerous NSAIDs as GI irritation, bleeding, and ulceration⁸. Several studies revealed that COX-2 is highly expressed in a wide range of cancer tissues, such as colon, breast, and prostate, suggesting that it may control several cellular processes. Thus, selective COX-2 inhibitors have been extensively investigated for the treatment and prevention of a variety of cancer⁹.

Also, COX-2 is found in wide range of tissues e.g. brain, spinal cord, and kidneys, as well as many cells like vascular endothelium, suggesting that this isoenzyme may play a more complex physiological role than was expected^{10,11}.

However, potent selective COX-2 inhibitors, which were used instead of NSAIDs; also showed disadvantages as incidence of vascular-diseases¹². AA; which is the substrate of COX enzymes, is also converted by LOX enzyme to several lipid mediators recognised as eicosanoids¹³. LOXs are an exceptional group of nonhaem iron-containing enzymes that catalyse the peroxidation of polyunsaturated fatty acids *viz*. AA and linoleic acid to their hydroperoxides¹⁴. 15-LOXs are implicated in a variety of human diseases, like the oxidative alteration of low-density lipoproteins and thus, the progression of atherosclerosis¹⁵. In addition to many neurodegenerative diseases as Alzheimer's disease¹⁶, 15-LOX-1 inhibition has been reported to be a focal point to decrease the biosynthesis of eoxines, which are known to be pro-inflammatory

 $\ensuremath{\mathbb{C}}$ 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

CONTACT Rania H. Abd El-Hameed 🔯 zeiadomar@yahoo.com 🗗 Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Ain-Helwan, Helwan, Cairo, Egypt

Supplemental data for this article can be accessed here.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

mediators¹⁷ and promotors for cancer disease¹⁸. Thus, some literature work has been targeting 15-LOX-1.

Yet, the use of LOX-inhibitors might represent an insufficient single therapeutic model in inflammatory diseases other than asthma^{19,20}. It was discovered that dual inhibition of the COX and LOX pathways could produce a wider spectrum of anti-inflammatory effects and can limit the vascular-changes seen during inflammation and leukocyte-induced GI damage²¹.

2-Furanones; well-known heterocyclic derivatives; had attracted a great attention during the last decade due to facile ring opening and conversion to other heterocycles; pyrrolones, pyridazinones, pyrazoles, and oxadizoles. These heterocycles acquired an obvious medicinal interest as antimicrobial^{22–24}, antiviral^{25–27}, antimycobacterial^{28,29}, and anti-cancer agents^{30–32}. Literature is enriched with different 2-furanones subjected to ring opening to form 2-pyrrolone, pyridazinone, and oxadiazole derivatives, all have high activity as anti-inflammatory^{24,33–41}. As shown in Figure 1, 2-furanone derivatives **Ia–c** were reported to exhibit comparable anti-inflammatory activity to that of diclofenac^{33,35,36}, while 2-pyrrolone derivatives **II, IIIa–b**, and **IV** were reported to have comparable anti-inflammatory activity to that of indomethacin, ibuprofen, and diclofenac, respectively^{24,34–36}.

Many pyridazinone derivatives were also reported as **Va,b**; which have superior anti-inflammatory activities over celecoxib and indomethacin, while derivatives **VIa-c** were more potent than aminopyrine, mebirizole, phenylbutazone, and mefenamic acid^{37,38}. Some of oxadiazole derivatives **VIIa,b** showed superior

activity over celecoxib besides compounds **VIIIa,b**; which were reported to be comparable with ibuprofen as dual COX/LOX inhibition activity^{42,43}.

The anti-inflammatory activity shown by the above derivatives has drawn our interest to continue our research^{44–46} for development of new anti-inflammatory agents. The synthesis and biological evaluation of new 2-furanone derivatives are reported herein. Also 2-furanone derivatives were used for synthesis of other heterocyclic and non-heterocyclic derivatives, which were tested as for their potential as anti-inflammatory agents against COX enzymes, LOX, and tumour necrosis factor- α (TNF- α).

2. Materials and methods

2.1. Synthesis of lead compounds

All commercial chemicals used as starting materials and reagents in this study were purchased from Merck (Darmstadt, Germany) and were of reagent grade. All melting points were uncorrected and measured using Electro-thermal IA 9100 apparatus (Shimadzu, Japan); IR spectra were recorded as potassium bromide pellets on a Perkin-Elmer 1650 spectrophotometer (Waltham MA, Faculty of Science, Cairo University, Cairo, Egypt. ¹H-NMR spectra were determined on a Varian Mercury (300 MHz) spectrometer (Varian, Crawley, UK) and chemical shifts were expressed as ppm against TMS as internal reference (The Main Chemical warfare Laboratories, Almaza, Cairo, Egypt). Mass spectra were recorded on 70 eV (El Ms-QP 1000 EX, Shimadzu, Japan), Faculty of Science,



Ia: Ar1= 4-CH₃-C₆H₅ Ar2=3-OC₂H₅,4-OCOCH₃-C₆H₃

Ib: Ar1=2-naphthyl, Ar2=2,7-Cl-3-quinolinyl **Ic:** Ar1=2-naphthyl, Ar2=2-Cl,7-NO₂-3-quinolinyl



Va: R1=H, R2=3-CH₃-C₆H₄, X=H **Vb:** R1=4-F-C₆H₄, R2=2-CH₃OC₆H₄, X=H **VIa:** R1=CH₃, R2=n-C₃H₇O, X=N-morpholinyl **VIb:** R1=CH₃, R2=n-C₄H₉O, X=N-morpholinyl **VIc:** R1=C₁H₅, R2=C₂H₅O, X=N-morpholinyl



II Ar1=4-OPh-C₆H₄, Ar2=3,4,5-OCH₃-C₆H₂ X=CH₂-Ph

IIIa: Ar1=4-Cl-C₆H₄, Ar2=4-Cl-C₆H₄

IIIb: Ar1=4-F-C₆H₄, Ar2=4-Cl-C₆H₄ X=CH₂-Ph

IV: Ar1=2-naphthyl, Ar2=2,7-Cl-3-quinolinyl X=H

VIIa: $R1=C_6H_4SO_2CH_3$, $R2=4-NO_2-C_6H_4$ **VIIb:** $R1=C_6H_4SO2CH_3$, $R2=4-tBu-C_6H_4$ **VIIIa:** $R1=4-Cl-C_6H_4$, R2=Chromon-3-yl**VIIIb:** $R1=2,4-Cl_2C_6H_3$, R2=Chromon-3-yl

Figure 1. 2-furanones, 2-pyrrolones, pyridazinones, and oxadiazoles as potent anti-inflammatory agents.

Cairo University, Cairo, Egypt. Microanalyses were operated using Vario, Elmentar apparatus (Shimadzu, Japan), Organic Microanalysis Unit, Faculty of Science, Cairo University, Cairo, Egypt. Column Chromatography was performed on (Merck) Silica gel 60 (particle size 0.06–0.20 mm). All the listed compounds are new except compound **1** was previously reported^{47,48}.

2.1.1. General procedure for the synthesis of compounds 2a-c

A mixture of compound **1** (0.03 mol) and equimolar amount of aromatic aldehyde was refluxed in acetic anhydride (15 ml) with triethylamine (3–4 drops) for 4 h. After completion of reaction, the product was filtered, washed with ethanol, and recrystallised from ethanol to obtain compounds **2a–c**.

2.1.1. 5-(3,4-Dichlorophenyl)3-(2-nitrobenzylidene)-furan-2-one (**2a**). Yield: 57%; m.p.: 259–261 °C; IR (KBr) ν (cm⁻¹): 1769 (C=O), 1515,1337 (NO₂); MS (EI) *m/z*: 363 (M + 2, 9.35%), 361 (M, 14.24%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 7.51–8.20 (m, 9H, Ar-H + CH methyne); Anal. Calcd. for C₁₇H₉Cl₂NO₄ (361.05): C, 56.51; H, 2.49; N, 3.88%. Found: C, 56.69; H, 2.81; N, 3.54%.

2.1.1.2. 5-(3,4-Dichlorophenyl)3-(3-nitrobenzylidene)-furan-2-one (**2b**). Yield: 90%; m.p.: 230–232 °C; IR (KBr) ν (cm⁻¹): 1781 (C=O), 1519,1345 (NO₂); MS (EI) *m/z*: 363 (M + 2, 23.28%), 361 (M, 34.48%), 173 (benzoyl, 100%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 7.23–8.67 (m, 9H, Ar-H + CH methyne); Anal. Calcd. for C₁₇H₉Cl₂NO₄ (361.05): C, 56.51; H, 2.49; N, 3.88%. Found: C, 56.26; H, 2.35; N, 3.76%.

2.1.1.3. 5-(3,4-Dichlorophenyl)3-(4-dimethylaminobenzylidene)furan-2-one (2c). Yield: 73%; m.p.: $204-206 \,^{\circ}$ C; IR (KBr) ν (cm⁻¹): 1748 (C=O); MS (EI) *m/z*: 361 (M + 2, 12.99%), 359 (M, 19.98%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 3.05 (s, 6H, N(CH₃)₂), 6.75-8.11 (m, 9H, Ar-H + CH methyne); Anal. Calcd. for C₁₉H₁₅Cl₂NO₂ (359.05): C, 63.51; H, 4.18; N, 3.90%. Found: C, 63.29; H, 3.96; N, 3.98%.

2.1.2. General procedure for the synthesis of compounds 3a-c

A solution of the furanone derivatives 2a-c (0.01 mol) and ammonium acetate (7.7 g, 0.1 mol) in acetic acid (10 ml) was refluxed for 3 h. The reaction mixture was left to cool at room temperature and the product obtained was filtered off, recrystallised from ethanol to give compounds **3a–c**.

2.1.2.1. 5-(3,4-Dichlorophenyl)-3-(2-nitrobenzylidene)-1H-pyrrol-2one (3a). Yield: 80%; m.p.: >300 °C; IR (KBr) ν (cm⁻¹): 3140 (NH), 1698 (C=O), 1514, 1350 (NO₂); MS (EI) *m/z*: 362 (M + 2, 10.78%), 360 (M⁺, 16.29%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 6.80–8.17 (m, 9H, Ar-H + CH methyne), 10.72 (s, 1H, NH, D₂O-exchangable); Anal. Calcd. for C₁₇H₁₀Cl₂N₂O₃ (360.02): C, 56.67; H, 2.78; N, 7.78%. Found: C, 56.81; H, 2.55; N, 7.46%.

2.1.2.2. 5-(3,4-Dichlorophenyl)-3-(3-nitrobenzylidene)-1H-pyrrol-2one (3b). Yield: 70%; m.p.: >300 °C; IR (KBr) ν (cm⁻¹): 3143 (NH), 1704 (C=O), 1517, 1355 (NO₂); MS (EI) *m/z*: 362 (M + 2, 67.3%), 360 (M⁺, 100%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 7.05–8.57 (m, 9H, Ar-H + CH methyne), 10.68 (s, 1H, NH, D₂O-exchangable); Anal. Calcd. for C₁₇H₁₀Cl₂N₂O₃ (360.02): C, 56.67; H, 2.78; N, 7.78%. Found: C, 56.52; H, 2.45; N, 7.43%. **2.1.2.3.** *5*-(*3*,*4*-Dichlorophenyl)-3-(*4*-dimethylaminobenzylidene)-1*H*pyrrol-2-one (*3c*). Yield: 56%; m.p.: >300 °C; IR (KBr) ν (cm⁻¹): 3697 (NH), 1673 (C=O); MS (EI) *m/z*: 360 (M + 2, 43.58%), 358 (M⁺, 62%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 2.98 (s, 6H, N(CH₃)₂), 6.46–8.37 (m, 9H, Ar-H+CH methyne), 10.37 (s, 1H, NH, D₂O-exchangable); Anal. Calcd. for C₁₉H₁₆Cl₂N₂O (358.05): C, 63.52; H, 4.49; N, 7.80%. Found: C, 63.21; H, 4.56; N, 7.34%.

2.1.3. General procedure for the synthesis of compounds 4a-c

To a solution of the furanone 2a-c (0.01 mol) in absolute ethanol (20 ml), benzylamine (1.07 ml, 0.01 mol) was added and the reaction mixture was refluxed for 5 h. The product was filtered off, washed with ethanol, and finally recrystallised from ethanol to give the amides **4a-c**.

2.1.3.1. *N*-benzyl-2-(2-nitrobenzylidene)-4-(3,4-dichlorophenyl)-4oxobutanamide (4a). Yield: 30%; m.p.: 250–252 °C; IR (KBr) ν (cm⁻¹): 3310 (NH), 1681, 1647 (2 C=O), 1559, 1336 (NO₂); MS (EI) *m/z*: 468 (M⁺, 0.33%), 91 (tropylium, 100%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 3.40 (s, 2H, CH₂–C=O), 4.36 (dd, 2H, CH₂–NH), 7.10 (s, 1H, NH, D₂O-exchangable), 7.11–8.80 (m, 13H, Ar-H + CH-methyne); Anal. Calcd. for C₂₄H₁₈Cl₂N₂O₄ (468.07): C, 61.42; H, 3.87; N, 5.97%. Found: C, 61.32; H, 3.51; N, 5.82%.

2.1.3.2. *N-benzyl-2-(3-nitrobenzylidene)-4-(3,4-dichlorophenyl)-4oxobutanamide (4b).* Yield: 70%; m.p.: 124–126°C; IR (KBr) ν (cm⁻¹): 3312 (NH), 1676, 1648 (2 C=O), 1530, 1350 (NO₂); MS (EI) *m/z*: 468 (M⁺, 0.29%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 3.61 (s, 2H, CH₂-CO), 4.21 (dd, 2H, CH₂-NH), 7.05–8.35 (m, 12H, Ar-H+CH-methyne+s, 1H, NH, D₂O-exchangable); Anal. Calcd. for C₂₄H₁₈Cl₂N₂O₄ (468.07): C, 61.42; H, 3.87; N, 5.97%. Found: C, 61.35; H, 3.74; N, 5.82%.

2.1.3.3. *N*-benzyl-2-(4-dimethylaminobenzylidene]-4-(3,4-dichlorophenyl)-4-oxobutanamide (4c). Yield: 40%; m.p.: 241–243 °C; IR (KBr) ν (cm⁻¹): 3300 (NH), 1756, 1670 (2 C=O); MS (EI) *m/z*: 468 (M + 2, 1.73%), 466 (M, 3.15%), 448 (M⁺-H₂O, 56.15%), 91 (tropylium, 100%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 2.88 (s,6H, N(CH₃)₂), 3.26 (s, 2H, CH₂-CO), 4.20 (dd, 2H, CH₂–NH), 6.93 (s, 1H, NH, D₂O-exchangable), 6.69–7.43 (m, 13H, Ar-H + CH-methyne); Anal. Calcd. for C₂₆H₂₄Cl₂N₂O₂ (466.09): C, 66.81; H, 5.18; N, 5.99%. Found: C, 66.75; H, 5.24; N, 5.86%.

2.1.4. General procedure for the synthesis of compounds 5a-c

A solution of the furanone 2a-c (0.01 mol) and phenyl hydrazine 3 ml in Na ethoxide (10 ml) was refluxed for 3 h. The product obtained was filtered, washed with water, and recrystallised from ethanol to give compounds **5a**–c.

2.1.4.1. 6-(3,4-Dichlorophenyl)-4-(2-nitrobenzylidene)-1-phenyl-1,4dihydropyridazin-3(2H)-one (5a). Yield: 72%; m.p.: >300 °C; IR (KBr) ν (cm⁻¹): 3317 (NH), 1629 (C=O), 1556, 1320 (NO₂); MS (EI) *m/z*: 451 (M⁺, 0.49%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 7.46–8.77 (m, 15H, Ar-H + CH-methyne + NH-D₂O exchangeable); Anal. Calcd. for C₂₃H₁₅Cl₂N₃O₃ (451.04): C, 61.08; H, 3.34; N, 9.29%. Found: C, 61.29; H, 3.74; N, 9.35%.

2.1.4.2. 6-(3,4-Dichlorophenyl)-4-(3-nitrobenzylidene)-1-phenyl-1,4dihydropyridazin-3(2H)-one (5b). Yield: 69%; m.p.: >300 °C; IR (KBr) ν (cm⁻¹): 3456 (NH), 1671 (C=O), 1549, 1328 (NO₂); MS (EI) *m/z*: 451 (M⁺, 1.56%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 7.16–8.49 (m, 15H, Ar-H + CH-methyne + NH-D₂O exchangeable); Anal. Calcd. for C₂₃H₁₅Cl₂N₃O₃ (451.04): C, 61.08; H, 3.34; N, 9.29%. Found: C, 61.28; H, 3.61; N, 9.35%.

2.1.4.3. 6-(3,4-Dichlorophenyl)-4-(4-dimethylaminobenzylidene)-1phenyl-1,4-dihydropyridazin-3(2H)-one (5c). Yield: 43%; m.p.: >300 °C; IR (KBr) ν (cm⁻¹): 3300 (NH), 1655 (C=O); MS (EI) *m/z*: 449 (M⁺, 1.63%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 2.86 (s,6H, N(CH₃)₂), 6.55–8.51 (m, 15H, Ar-H + CH-methyne + NH-D₂O exchangeable); Anal. Calcd. for C₂₅H₂₁Cl₂N₃O (449.04): C, 66.67; H, 4.70; N, 9.33%. Found: C, 66.46; H, 5.12; N, 9.17%.

2.1.5. General procedure for the synthesis of compounds 6a-c

To a solution of the furanones 2a-c (0.01 mol) in absolute ethanol (20 ml), hydrazine hydrate (3.5 ml, 0.11 mol) was added. The reaction mixture was left at room temperature with occasional shaking until complete dissolving and poured onto ice water. The product obtained **6a-c** was filtered off, washed with hexane.

2.1.5.1. 4-(3,4-Dichlorophenyl)-2-(2-nitrobenzylidene)-4-oxo-buta*nehydrazide* (*6a*). Yield: 65%; m.p.: 164–166 °C; IR (KBr) ν (cm⁻¹): 3322 (NH), 3250 (NH₂), 1703,1670 (2 C=O), 1521, 1343 (NO₂); MS (EI) *m/z*: 395 (M + 2, 0.37%), 393 (M⁺, 0.47%), 364 (M + 2 - NHNH₂, 21.29%), 362 (M - NHNH₂, 31.7%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 3.17 (s, 2H, CH₂), 4.55 (s, 2H, NH₂, D₂O-exchangable), 6.87 (s, 1H, NHCO, D₂O-exchangable), 7.32–8.06 (m, 8H, Ar-H + CH-methyne); Anal. Calcd. for C₁₇H₁₃Cl₂N₃O₄ (393.04): C, 51.91; H, 4.33; N, 10.69%. Found: C, 51.77; H, 4.51; N, 10.58%.

2.1.5.2. 4-(3,4-Dichlorophenyl)-2-(3-nitrobenzylidene)-4-oxo-buta*nehydrazide* (*6b*). Yield: 58%; m.p.: 160–162 °C; IR (KBr) ν (cm⁻¹): 3315 (NH), 3257 (NH₂), 1697,1656 (2 C=O), 1528, 1360 (NO₂); MS (El) *m/z*: 393 (M⁺, 0.27%), 375 (M – H₂O, 100%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 3.24 (s, 2H, CH₂), 4.57 (s, 2H, NH₂, D₂O-exchangable), 6.92 (s, 1H, NHCO, D₂O-exchangable), 7.35–8.32 (m, 8H, Ar-H + CH-methyne); Anal. Calcd. for C₁₇H₁₃Cl₂N₃O₄ (393.04): C, 51.91; H, 4.33; N, 10.69%. Found: C, 51.75; H, 4.55; N, 10.74%.

2.1.5.3. 4-(3,4-Dichlorophenyl)-2-(4-dimethylaminobenzylidene)-4oxo-butanehydrazide (6c). Yield: 56%; m.p.: 154–156°C; IR (KBr) ν (cm⁻¹): 3310 (NH), 3258 (NH₂), 1751,1672 (2C=O); MS (EI) *m/z*: 393 (M+2, 9.38%), 391 (M⁺, 14.69%), 364 (M+2 - NHNH₂, 32.60%), 360 (M - NHNH₂, 47.87%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 2.82 (s, 2H, CH₂), 2.92 (s, 6H, N(CH₃)₂), 4.39 (s, 2H, NH₂, D₂O-exchangable), 6.73 (s, 1H, NHCO, D₂O-exchangable), 6.67–7.61 (m, 8H, Ar-H+CH-methyne); Anal. Calcd. for C₁₉H₁₉Cl₂N₃O₂ (391.01): C, 58.31; H, 4.86; N, 10.74%. Found: C, 58.66; H, 5.05; N, 10.77%.

2.1.6. General procedure for the synthesis of compounds 7a-c

Method 1: A solution of hydrazides **6a**-c (0.01 mol) in HCI/AcOH (1:3) was refluxed for 3 h. The solid that separated after concentration and cooling was recrystallised from ethanol to obtain compounds **7a**-c.

Method 2: To a solution of the furanones 2a-c (0.01 mol) in absolute ethanol (20 ml), hydrazine hydrate (3.5 ml, 0.11 mol) was added. The reaction mixture was refluxed for 4 h, then cooled and poured onto ice water. The product obtained **7a-c** was filtered off, washed with hexane.

2.1.6.1. 3-(3,4-Dichlorophenyl)-5-[(2-nitropheny)l-methyl]-1H-pyridazin-6-one (7a). Yield: 85%; m.p.: 224–226 °C; IR (KBr) ν (cm⁻¹): 3187 (NH), 1655 (C=O), 1517 + 1343 (NO2); MS (EI) *m/z*: 377 (M + 2, 2.63%), 375 (M⁺, 3.8%), 330 (M + 2-NO₂, 63.21%), 329 (M - NO₂, 100%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 4.13 (s, 2H, CH₂), 7.49–8.00 (m, 8H, Ar-H), 13.32 (s, 1H, NH-pyridazinone, D₂O-exchangable); Anal. Calcd. for C₁₇H₁₁Cl₂N₃O₃(375.04): C, 54.40; H, 2.93; N, 11.20%. Found: C, 54.72; H, 3.05; N, 11.08%.

2.1.6.2. 3-(3,4-Dichlorophenyl)-5-[(3-nitropheny)l-methyl]-1H-pyridazin-6-one (7b). Yield: 43%; m.p.: 257-259 °C; IR (KBr) ν (cm⁻¹): 3203 (NH), 1653 (C=O), 1527 + 1346 (NO2); MS (EI) *m/z*: 377 (M + 2, 6.56%), 375 (M⁺, 10.06%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 4.01 (s, 2H, CH₂), 7.59–8.25 (m, 8H, Ar-H), 13.34 (s, 1H, NH-pyridazinone, D₂O-exchangable); Anal. Calcd. for C₁₇H₁₁Cl₂N₃O₃(375.04): C, 54.40; H, 2.93; N, 11.20%. Found: C, 54.32; H, 2.83; N, 11.32%.

2.1.6.3. 3-(3,4-DichlorophenyI)-5-[(4-dimethylaminopheny)/- methyl]-1H-pyridazin-6-one (7c). Yield: 87%; m.p.: 229–231°C; IR (KBr) ν (cm⁻¹): 3164 (NH), 1651 (C=O); MS (EI) *m/z*: 377 (M + 4, 12.06%), 375 (M + 2, 67.79%), 373 (M⁺, 100%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 2.81 (s, 6H, N(CH₃)₂), 3.70 (s, 2H, CH₂), 6.62–8.06 (m, 8H, Ar-H), 13.19 (s, 1H, NH-pyridazinone, D₂O-exchangable); Anal. Calcd. for C₁₉H₁₇Cl₂N₃O (373.09): C, 61.13; H, 4.56; N, 11.26%. Found: C, 61.33; H, 4.54; N, 10.99%.

2.1.7. General procedure for the synthesis of compounds 8a-c

To a solution of the hydrazides 6a-c (0.01 mol) in dry benzene (20 ml), benzoyl chloride (1.4 ml, 0.01 mol) was added. The reaction mixture was heated under reflux for 2 h. The solvent was evaporated, and the solid obtained was washed thoroughly with ethanol, drained, and recrystallised from hexane to give compounds **8a–c**.

2.1.7.1. 2-Benzoyl-5-(2-nitrobenzylidene)-3-(3,4-dichlorophenyl)-1Hpyridazin-6-one (8a). Yield: 84%; m.p.: 222–224°C; IR (KBr) ν (cm⁻¹): 3275 (NH), 1740,1660 (2 C=O),1512, 1343 (NO2); MS (EI) m/z: 481 (M + 2, 1.17%), 479 (M⁺, 1.69%), 105 (benzoyl, 100%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 6.69 (s, 1H, CH-methyne),7.48–8.20 (m, 13H, Ar-H), 11.30 (s, 1H, NH, D₂O-exchangable); Anal. Calcd. for C₂₄H₁₅Cl₂N₃O₄ (479.04): C, 60.02; H, 3.15; N, 8.75%. Found: C, 60.34; H, 3.01; N, 8.94%.

2.1.7.2. 2-Benzoyl-5-(3-nitrobenzylidene)-3-(3,4-dichlorophenyl)-1Hpyridazin-6-one (8b). Yield: 40%; m.p.: 150–152°C; IR (KBr) ν (cm⁻¹): 3250 (NH), 1717,1677 (2 C=O),1523, 1350 (NO2); MS (EI) m/z: 479 (M⁺, 2.82%), 105 (benzoyl, 100%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 7.03–8.59 (m, 13H, Ar-H + CH-methyne), 11.34 (s, 1H, NH, D₂O-exchangable); Anal. Calcd. for C₂₄H₁₅Cl₂N₃O₄ (479.04): C, 60.02; H, 3.15; N, 8.75%. Found: C, 60.12; H, 3.56; N, 8.91%.

2.1.7.3. 2-Benzoyl-5-(4-dimethylaminobenzylidene)-3-(3,4-dichlorophenyl)-1H-pyridazin-6-one (8c). Yield: 37%; m.p.: 229–231 °C; IR (KBr) ν (cm⁻¹): 3225 (NH), 1687,1664 (2 C=O); MS (EI) *m/z*: 479 (M + 2, 33.09%), 474 (M⁺, 49.44%), 105 (benzoyl, 100%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 3.03 (s, 6H, N(CH₃)₂), 6.76–8.01 (m, 14H, Ar-H+CH-methyne), 11.17 (s, 1H, NH, D₂O-exchangable); Anal. Calcd. for C₂₆H₂₁Cl₂N₃O₂ (477.09): C, 65.28; H, 4.42; N, 8.78%. Found: C, 65.31; H, 4.68; N, 8.23%.

2.1.8. General procedure for the synthesis of compounds 9a-cA solution of hydrazides **6a-c** (0.01 mol) and carbon disulphide (3 ml) in pyridine (10 ml) was refluxed for 3 h. The reaction mixture was left to cool at room temperature and poured onto ice water; the product obtained was filtered, washed with water and recrystallised from ethanol to give compounds **9a-c**.

2.1.8.1. 1-(3,4-Dichlorophenyl)-4-(2-nitrophenyl)-3-(2-thioxo-4,5dihydro-1,3,4-oxadiazol-5-yl)but-3-en-1-one (9a). Yield: 40%; m.p.: 214–216 °C; IR (KBr) ν (cm⁻¹): 3196 (NH), 1653 (C=O),1504, 1340 (NO₂), 1254 (C=S); MS (EI) *m/z*: 435 (M⁺, 0.31%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 4.13 (s, 2H, CH₂), 7.36–8.00 (m, 8H, Ar-H + CH-methyne), 13.32 (s, 1H, NH, D₂O-exchangable); Anal. Calcd. for C₁₈H₁₁Cl₂N₃O₄S (435.04): C, 49.56; H, 2.54; N, 9.63%. Found: C, 49.38; H, 2.76; N, 9.54%.

2.1.8.2. 1-(3,4-Dichlorophenyl)-4-(3-nitrophenyl)-3-(2-thioxo-4,5dihydro-1,3,4-oxadiazol-5-yl)but-3-en-1-one (9b). Yield: 58%; m.p.: 242–244 °C; IR (KBr) ν (cm⁻¹): 3195 (NH), 1653 (C=O),1514, 1346 (NO₂), 1238 (C=S); MS (EI) *m/z*: 435 (M⁺, 0.07%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 3.99 (s, 2H, CH₂), 7.38–8.57 (m, 8H, Ar-H + CH-methyne), 13.32 (s, 1H, NH, D₂O-exchangable); Anal. Calcd. for C₁₈H₁₁Cl₂N₃O₄S (435.04): C, 49.56; H, 2.54; N, 9.63%. Found: C, 49.37; H, 2.34; N, 9.41%.

2.1.8.3. *1-(3,4-Dichlorophenyl)-4-(4-dimethylaminophenyl)-3-(2-thioxo-4,5-dihydro-1,3,4-oxadiazol-5-yl)but-3-en-1-one (9c).* Yield: 89%; m.p.: 162–164 °C; IR (KBr) ν (cm⁻¹): 3200 (NH), 1655 (C=O), 1230 (C=S); MS (EI) *m/z*: 433 (M⁺, 1.4%); ¹H-NMR (DMSO-d₆, 300 MHz) δ (ppm): 2.84 (s, 6H, N(CH₃)₂), 3.72 (s, 2H, CH₂), 6.65–8.59 (m, 8H, Ar-H+CH-methyne), 13.22 (s, 1H, NH, D₂O-exchangable); Anal. Calcd. for C₂₀H₁₇Cl₂N₃O₂S (433.04): C, 55.31; H, 3.95; N, 9.67%. Found: C, 55.64; H, 3.47; N, 9.21%.

2.2. Biological evaluation of anti-inflammatory activity

2.2.1. Cyclooxygenase (COX-1 and COX-2) inhibition assay

Tested compounds were dissolved in DMSO. Each compound was tested in triplicates using a COX inhibitory screening assay kit according to the manufacturer (Cayman test kit-560131, Cayman Chemical, Ann Arbor, MI). The COX inhibitor screening assay depends on direct measurement of the amount of $PG2\alpha$ produced in the COX reaction. Celecoxib, rofecoxib, and indomethacin were used as the positive control for inhibition of COX-1 and COX-2. An aliquot of 20 µl of each test compound or solvent (100% initial activity) was added to 950 µl of Reaction Buffer (0.1 M Tris-HCl, pH 8.0, containing 5 mM EDTA and 2 mM phenol), 10 μ l of haem, and $10\,\mu$ l of COX-1 or COX-2, then incubated with the enzymes at $37 \,^{\circ}\text{C}$ for 10 min. The reaction was initiated by addition of $10 \,\mu\text{I}$ AA to all the test tubes and incubation at 37 °C for an additional 2 min. Enzyme catalysis was terminated by addition of $50 \, \mu l \, 1 \, M$ HCl and 100 μl of the saturated stannous chloride solution. The PGs are quantified by enzyme immunoassay (EIA) at 410 nm.

2.2.2. Lipoxygenase (15-LOX) inhibition assay

The experiment was performed in triplicates using Cayman's LOX inhibitor screening assay kit (Cayman test kit-760700, Cayman Chemical, Ann Arbor, MI) according to the manufacturer's protocol. DMSO was used as 100% initial activity and Quercetin was used as the positive control. Briefly, in a 96-well plate, $10 \,\mu$ l of each test compound (dissolved in DMSO) or vehicle were

2.2.3. TNF- α [biotinylated] inhibition assay

The assay was performed in triplicates using TNFR2: TNF- α [biotinylated] Inhibitor Screening Assay Kit (BPS bioscience, San Diego, CA, Catalog #79756), following the manufacturer's protocol. First, TNFR2 is coated on a 96-well plate. Next, biotinylated TNF- α is incubated with TNFR2 on the plate. Finally, the plate was treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can be measured using a chemiluminescence reader.

3. Results and discussion

3.1. Chemistry

Overall, 22 new compounds and two reported compounds were synthesised as revealed in Schemes A and B. 2-Furanone derivatives **2a–c** were synthesised from 4-oxobutanoic derivative **1** by reacting with aromatic aldehydes in acetic anhydride following modified Perkin reaction conditions^{23,27–29,35}.

The required 4-oxobutanoic derivative **1** was prepared by condensing dry dichlorobenzene with succinic anhydride in presence of anhydrous aluminium chloride, following Friedel–Crafts acylation reaction conditions.

As revealed in Scheme A, 2-furanone derivatives **2a-c** proved to be useful precursors in the synthesis of several heterocyclic and non-heterocyclic derivatives. When they were allowed to react, separately, with ammonium acetate; pyrrol-2-one derivatives **3a-c** were produced. 4-oxobutanamides **4a-c** were prepared by refluxing 2-furanones **2a-c** with benzylamine and 1-phenylpyridazinone **5a-c** were also prepared from 2-furanones by refluxing with phenyl hydrazine according to the reported procedure^{29,31}.

Pyridazinone derivatives **7a-c** can be prepared by first stirring of 2-furanone derivatives **2a-c** with hydrazine hydrate to obtain hydrazide derivatives **6a-c** which can be cyclised by refluxing in HCl to obtain the desired pyridazinone derivatives **7a-c**. They can be prepared directly by refluxing 2-furanone derivatives **2a-c** with hydrazine hydrate.

Hydrazide derivatives **6a–c** were refluxed with benzoyl chloride to obtain 2-benzoylpyridazinone derivatives **8a–c**.

Finally, oxadiazole-thione derivatives **9a–c** were prepared *via* refluxing hydrazide derivatives **6a–c** with carbon disulphide in pyridine^{2,22,23,27,49} as revealed in Scheme B.

3.2. Anti-inflammatory activity results

Inflammation is a protective defence response of the body. However, during inflammation, several pathological changes occur, which involve the release of common mediators of inflammation like PGs, histamine, nitric oxide, leukotrienes (LTB4), plate-let-activation factor, lipoxins, and cytokines⁵⁰. The inflammatory response must be terminated; using anti-inflammatory compounds, when no more needed to prevent avoidable harmful biological processes⁵¹. Inhibition of eicosanoids generation, in addition to the release of the pro-inflammatory cytokine; TNF- α from macrophages are used for *in vitro* inflammation tests⁵².



Scheme A. Synthesis of compounds 2a-c to 5a-c.



Scheme B. Synthesis of compounds 6a-c to 9a-c.

Thus, the newly synthesised compounds were tested for their anti-inflammatory activity against isozymes COX-1 and COX-2, which were determined by the COX-catalysed transformation of AA into PGH2 that was reduced to PGF2 α and detected by the EIA⁵³, as shown in Table 1.

Compound **2c** was the most potent COX-1 inhibitor (IC₅₀ $3.93 \pm 0.06 \,\mu$ M) among test compounds, being 39 times less active than the reference drug indomethacin (IC₅₀=0.10 μ M) indicating the selective COX-2 inhibition activity of all test compounds. Pyridazinone derivatives **5b**, **8b**, and **8c** were the most potent

Table 1. COX-1, COX-2, and 15-LOX enzymes inhibition activities of the synthesised compounds.

	COX1	COX 2	Selectivity indexes	LOX
Compound number	IC ₅₀ (μm)	IC ₅₀ (μm)	(SI)	IC ₅₀ (μm)
2a	4.53 ± 0.12	0.35 ± 0.01	12.94	5.10 ± 0.10
2b	6.97 ± 0.12	0.28 ± 0.01	24.89	4.40 ± 0.10
2c	3.93 ± 0.06	0.42 ± 0.02	9.36	6.13 ± 0.12
3a	8.37 ± 0.12	0.19 ± 0.01	44.05	2.33 ± 0.12
3b	6.87 ± 0.12	0.39 ± 0.01	17.62	1.87 ± 0.15
3c	5.93 ± 0.15	0.34 ± 0.01	17.44	2.21 ± 0.98
4a	11.07 ± 0.15	0.05 ± 0.00	221.40	5.47 ± 0.12
4b	13.33 ± 0.15	0.06 ± 0.00	222.17	5.87 ± 0.06
4c	11.90 ± 0.10	0.05 ± 0.00	238.00	4.67 ± 0.06
5a	12.73 ± 0.12	0.06 ± 0.00	212.17	2.70 ± 0.95
5b	13.00 ± 0.10	0.04 ± 0.00	325.00	2.43 ± 0.12
5c	11.73 ± 0.12	0.09 ± 0.00	130.33	2.97 ± 0.12
ба	9.67 ± 0.06	0.09 ± 0.00	107.44	2.83 ± 0.06
6b	10.07 ± 0.15	0.08 ± 0.00	125.88	2.47 ± 0.06
6с	8.83 ± 0.06	0.10 ± 0.01	88.30	3.17 ± 0.06
7a	7.03 ± 0.15	0.17 ± 0.01	41.35	5.47 ± 0.12
7b	6.67 ± 0.12	0.25 ± 0.01	26.68	5.87 ± 0.06
7c	8.33 ± 0.06	0.12 ± 0.01	69.42	4.67 ± 0.06
8a	10.77 ± 0.15	0.07 ± 0.00	153.86	2.33 ± 0.51
8b	12.67 ± 0.12	0.04 ± 0.00	316.75	2.47 ± 0.06
8c	13.07 ± 0.12	0.04 ± 0.00	326.75	3.17 ± 0.06
9a	9.43 ± 0.12	0.28 ± 0.01	33.68	2.07 ± 0.15
9b	10.43 ± 0.12	0.08 ± 0.00	130.38	1.63 ± 0.15
9c	8.93 ± 0.06	0.22 ± 0.01	40.59	2.00 ± 0.17
Celecoxib	14.70 ± 0.06	0.05 ± 0.00	326.67	ND
Rofecoxib	14.50 ± 0.10	0.03 ± 0.00	580.00	ND
Indomethacin	0.10 ± 0.00	0.08 ± 0.00	1.25	ND
Quercetin	ND	ND	ND	3.34 ± 0.05

Data are presented as mean \pm SD of three experiments.

ND: not determined; $SI = IC_{50}$ COX-1/COX-2 ratios.

selective COX-2 inhibitors (IC₅₀=0.04 μ M for the three compounds), being superior to the reference drug (celecoxib IC₅₀=0.05 μ M). While amide derivatives; **4a–c**, hydrazides; **6a, 6b**, N-phenyl and N-benzoylpyridazinones; **5a, 5c, 8a** and oxadiazole; **9b** (IC₅₀=0.05–0.09 μ M range), showed comparable activity to celecoxib as selective COX-2 inhibitors. These results indicate the high activity of hydrazides, pyridazinones, and oxadiazole; which is in consistent with previously reported activities of similar scaffolds as selective COX-2 inhibitors^{37,42,54–57}.

Studies showed that soybean LOX enzyme has a wide substrate specificity, and that the oxygenation sites for the soybean LOX has been demonstrated to be at C-13 of α -linolenic acid and C-15 of AA⁵⁸. Therefore, the soybean LOX is most like the mammalian 15-LOX⁵⁹.

Consequently, the *in vitro* inhibitory effect of all synthesised compounds against 15-LOX was determined using a lipoxygenation reaction to transform AA into hydroperoxides, which were detected by the addition of a chromogen, whose results are displayed in Table 1^{60} .

Results also revealed that all the synthesised derivatives of pyrrolones **3a-c**, hydrazides **6a-c**, N-phenyl and N-benzoylpyridazinones; **5a-c**, **8a-c**, and oxadiazoles **9a-c** inhibited 15-LOX (IC₅₀ = $1.63 - 3.17 \,\mu$ M range), **9b** being the most potent 15-LOX inhibitor (IC₅₀= $1.63 \pm 0.15 \,\mu$ M), compared to the positive control Quercetin (IC₅₀= $3.34 \,\mu$ M). However, furanones **2a-c**, amides **4a-c**, and pyridazinones **7a-c** exhibited lower 15-LOX inhibitory effect.

By evaluating the COX and 15-LOX inhibition results, three compounds namely 6–(3,4-dichlorophenyl)-4–(3-nitrobenzylidene)-1-phenyl-1,4-dihydropyridazin-3(2H)-one (**5b**), 2-benzoyl-5–(3-nitrobenzylidene)-3–(3,4-dichlorophenyl)-1H-pyridazin-6-one (**8b**), and 2-benzoyl-5–(4-dimethylaminobenzylidene)-3–(3,4-dichlorophenyl)-1H-pyridazin-6-one (**8c**) seemed to be the best candidates as a COX-2/15-LOX dual inhibitors, which is a current subject of

Table 2.	Inhibitory	effects	of	tested	compounds	against	TNF-α.
----------	------------	---------	----	--------	-----------	---------	--------

	TNF-α
Compound number	IC ₅₀ (nM)
2a	7.47±0.12
2b	7.77 ± 1.68
2c	8.20±0.10
3a	5.93 ± 0.15
3b	8.27 ± 0.12
3c	6.77 ± 0.12
4a	4.77 ± 0.12
4b	3.53 ± 0.12
4c	5.47 ± 0.12
5a	4.93 ± 0.06
5b	3.27 ± 0.12
5c	3.57 ± 0.12
ба	5.87 ± 0.12
6b	4.10 ± 0.10
бс	6.17 ± 0.06
7a	8.53 ± 0.12
7b	8.17 ± 0.06
7c	7.57 ± 0.06
8a	3.83 ± 1.44
8b	3.47 ± 0.06
8c	2.90 ± 0.10
9a	5.57 ± 0.06
9b	4.33 ± 0.12
9c	6.27 ± 0.15
Certolizumab	6.70±0.12

Data are presented as mean \pm SD of three experiments.

interest in the development of anti-inflammatory agents⁶⁰. This declares the expected activity of N-phenyl and N-benzoylpyridazinones derivatives as reported for some other derivatives with the same scaffold⁶¹. On the other hand, compounds **5a**, **5c**, **6a**, **6b**, **8a**, and **9b** exhibited a little lower COX-2 inhibition but still show high dual COX-2/15-LOX inhibition activity.

Moreover, the ability to inhibit TNF- α , which is a potent proinflammatory chemokine was tested; results are shown in Table 2. The 15-LOX pathway was reported to induce inflammation through increased expression of IL-6, IFN- γ , IL-12, and TNF- α^{62} .

Sixteen compounds of our newly synthesised tested compounds; pyrrolone **3a**, amides **4a–c**, N-phenylpyridazinones **5a–c**, hydrazides **6a–c**, N-benzoylpyridazinones **8a–c**, and oxadiazoles **9a–c** showed higher activities ($IC_{50} = 2.90 - 6.27 \mu$ M range) than the used reference inhibitor Certolizumab ($IC_{50}=6.70 \mu$ m). While compound **3c** showed comparable activity with $IC_{50}=6.77 \mu$ M. Compound **8c** showed the lowest IC_{50} value for TNF- α inhibition, indicating that this activity may be a consequence of 15-LOX inhibition.

To analyse the structure–activity relationship (SAR) of the tested compounds from the previous results, it is obvious that our three newly synthesised furanones are totally inactive towards all the tested enzymes. But upon their conversion to other heterocyclic and non-heterocyclic compounds the biological activities appear as revealed in Figure 2 and explained as follows:

3 Pyrrolone derivatives **3a–c** acquired high activity as LOXinhibitors, only one of them having 3-nitrobenzylidene substituent **(3b)** showed high activity as TNF- α inhibitor. They still have no significant activities as COX-2 inhibitors.

Upon ring opening and formation of amide derivatives **4a–c**, a high TNF- α inhibition appears with significant selective COX-2 inhibition, but no significant LOX-inhibition observed.

Also, ring opening and hydrazides formation in **6a–c** showed activity against 15-LOX and TNF- α , while **6a,b** having 2-nitroben-zylidene and 3-nitrobenzylidene substituents showed high activity as selective COX-2 inhibitors.



Figure 2. Structure-activity relationship of the tested compounds against the tested enzymes.

Conversion of furanones to pyridazinines **7a–c** did not affect their biological activities as they were still inactive. But formation of N-phenylpyridazinones **5a–c** and N-benzoylpyridazinones **8a–c** was a perfect pathway for highly potent derivatives against all the tested enzymes with desirable dual COX-2/15-LOX inhibition activities for compounds **5b**, **8b**, and **8c** indicating the important influence of presence of 3-nitrobenzylidene substituent in both pyridazinones (**5b**, **8b**) and 4-dimethylaminobenzylidene in N-benzoylpyridazinone (**8c**).

Finally, three oxadiazole derivatives **9a–c** showed high activity against 15-LOX and TNF- α , while two derivatives, having 2-nitrobenzylidene and 4-dimethylaminobenzylidene substituents, **9a** and **9c**, respectively, showed high activity as selective COX-2 inhibitors.

Conclusion

In conclusion, as presented in this study, novel 2-furanone derivatives were synthesised and used to prepare novel hydrazides, 2-pyrrolone, 2-pyridazinone, and oxadiazole derivatives. All the synthesised compounds were investigated for their anti-inflammatory activity; the biological results revealed that N-phenylpyridazinone **5b**, N-benzoylpyridazinones **8b** and **8c** showed promising activity as dual COX-2/15-LOX inhibitors along with high TNF- α inhibition activity. Thus, these compounds might be promising anti-inflammatory candidates and may need further studies to be used clinically.

Disclosure statement

Authors would like to declare that there are no relationships or interests that could have direct or potential influence or impart bias on the work.

Funding

Authors are grateful to Science and Technology Development Fund (STDF) for financial support of this research.

References

- 1. Dkhil MA, Kassab RB, Al-Quraishy S, et al. *Ziziphus spina*christi (l.) leaf extract alleviates myocardial and renal dysfunction associated with sepsis in mice. Biomed Pharmacother 2018;102:64–75.
- Park YD, Jin CH, Choi DS, et al. Biological evaluation of isoegomaketone isolated from perilla frutescens and its synthetic derivatives as anti-inflammatory agents. Arch Pharm Res 2011;34:1277–82.
- 3. Moilanen E. Two faces of inflammation: an immunopharmacological view. Basic Clin Pharmacol Toxicol 2014;114:2–6.
- You KM, Jong HG, Kim HP. Inhibition of cyclooxygenase/lipoxygenase from human platelets by polyhydroxylated/ methoxylated flavonoids isolated from medicinal plants. Arch Pharm Res 1999;22:18–24.
- Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994;91:2046–50.
- Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (cox) inhibition and beyond. J Pharm Pharm Sci 2008;11:81s–110s.
- Hosoda A, Ozaki Y, Kashiwada A, et al. Syntheses of ferulic acid derivatives and their suppressive effects on cyclooxygenase-2 promoter activity. Bioorg Med Chem 2002;10: 1189–96.
- Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992;327:749–54.

- 9. Kanaoka S, Takai T, Yoshida K. Cyclooxygenase-2 and tumor biology. Adv Clin Chem 2007;43:59–78.
- Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847–60.
- 11. Dannhardt G, Laufer S. Structural approaches to explain the selectivity of cox-2 inhibitors: is there a common pharmaco-phore? Curr Med Chem 2000;7:1101–12.
- 12. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (cox)-2: the human pharmacology of a selective inhibitor of cox-2. Proc Natl Acad Sci USA 1999;96:272–7.
- 13. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Ann Rev Biochem 2000;69:145–82.
- 14. Pontiki E, Hadjipavlou-Litina D. Lipoxygenases (los): an heterogenous family of lipid peroxidizing enzymes implicated in cell differentiation, inflammation, asthma, carcinogenesis, atherogenesis-an interesting target for the development of promising drugs. Curr Enzyme Inhib 2005;1:309–27.
- 15. Bocan TM, Rosebury WS, Mueller SB, et al. A specific 15-lipoxygenase inhibitor limits the progression and monocytemacrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis 1998;136: 203–16.
- 16. Pratico D, Zhukareva V, Yao Y, et al. 12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol 2004;164:1655–62.
- Feltenmark S, Gautam N, Brunnström Å, et al. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. Proc Natl Acad Sci USA 2008;105:680–5.
- Kelavkar U, Lin Y, Landsittel D, et al. The yin and yang of 15-lipoxygenase-1 and delta-desaturases: dietary omega-6 linoleic acid metabolic pathway in prostate. J Carcinogen 2006;5:9.
- 19. Weinblatt ME, Kremer JM, Coblyn JS, et al. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J Rheumatol 1992;19:1537–41.
- 20. Collawn C, Rubin P, Perez N, et al. Phase ii study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am J Gastroenterol 1992;87:342–6.
- 21. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-lox and cox, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2003;62:501–9.
- 22. Abou-Elmagd WS, El-Ziaty AK, Abdalha AA. Ring transformation and antimicrobial activity of indolyl-substituted 2 (3h)furanones. Heterocycl Commun 2015;21:179–85.
- 23. Ahmad A, Husain A, Khan SA, et al. Design, synthesis, molecular properties and antimicrobial activities of some novel 2 (3h) pyrrolone derivatives. J Saudi Chem Soc 2015; 19:340–6.
- 24. Husain A, Khan M, Hasan S, Alam M. 2-Arylidene-4-(4-phenoxy-phenyl)but-3-en-4-olides: synthesis, reactions and biological activity. Eur J Med Chem 2005;40:1394–404.
- 25. Flefel EM, Abdel-Mageid RE, Tantawy WA, Ali MA, et al. Heterocyclic compounds based on 3-(4-bromophenyl) azo-5phenyl-2(3h)-furanone: anti-avian influenza virus (h5n1) activity. Acta Pharm 2012;62:593–606.
- 26. Hashem AI, Youssef AS, Kandeel KA, Abou-Elmagd WS. Conversion of some 2(3h)-furanones bearing a pyrazolyl

group into other heterocyclic systems with a study of their antiviral activity. Eur J Med Chem 2007;42:934–9.

- Sayed HH, Hashem AI, Yousif NM, El-Sayed WA. Conversion of 3-arylazo-5-phenyl-2(3H)-furanones into other heterocycles of anticipated biological activity. Arch Der Pharm Int J Pharm Med Chem 2007;340:315–9.
- 28. Husain A, Ahmad A, Bhandari A, Ram V. Synthesis and antitubercular activity of pyridazinone derivatives. J Chilean Chem Soc 2011;56:778–80.
- 29. Husain A, Alam MM, Hasan SM, Yar MS. 2(3H)-furanones and 2(3H)-pyrrolones: synthesis and antimycobacterial evaluation . Acta Poloniae Pharm 2009;66:173–80.
- 30. Abou-Elmagd WS, Hashem Al. Synthesis and antitumor activity evaluation of some novel-fused and spiro heterocycles derived from a 2 (3h)-furanone derivative. J Heterocycl Chem 2016;53:202–8.
- 31. Abou-Elmagd WS, EL-Ziaty AK, Elzahar MI, et al. Synthesis and antitumor activity evaluation of some n-heterocycles derived from pyrazolyl-substituted 2 (3 h)-furanone. Synth Commun 2016;46:1197–208.
- 32. Wu YC, Cao L, Mei WJ, et al. Bis-2(5H)-furanone derivatives as new anticancer agents: design, synthesis, biological evaluation, and mechanism studies. Chem Biol Drug Design 2018; 92:1232–40.
- Husain A, Alam MM, Siddiqui N. Synthesis, reactions and biological activity of 3-arylidene-5-(4-methylphenyl)-2 (3h)furanones? J Serbian Chem Soc 2009;74:103–15.
- 34. Alam M, Husain A, Hasan S, Anwer T. Synthesis and pharmacological evaluation of 2 (3h)-furanones and 2 (3h)-pyrrolones, combining analgesic and anti-inflammatory properties with reduced gastrointestinal toxicity and lipid peroxidation. Eur J Med Chem 2009;44:2636–42.
- 35. Khokra SL, Kaushik P, Alam M, et al. Quinoline based furanones and their nitrogen analogues: docking, synthesis and biological evaluation. Saudi Pharm J 2016;24:705–17.
- Alam MM, Sarkar PD, Husain A, et al. Synthesis of quinoline attached-furan-2 (3h)-ones having anti-inflammatory and antibacterial properties with reduced gastro-intestinal toxicity and lipid peroxidation. J Serbian Chem Soc 2011;76: 1617–26.
- Ahmed EM, Kassab AE, El-Malah AA, Hassan MSA. Synthesis and biological evaluation of pyridazinone derivatives as selective cox-2 inhibitors and potential anti-inflammatory agents. Eur J Med Chem 2019;171:25–37.
- Takaya M, Sato M. [Studies on pyridazinone derivatives. XVI. Analgesic-antiinflammatory activities of 3(2H)-pyridazinone derivatives]. Yakugaku Zasshi: J Pharm Soc Jpn 1994;114: 94–110.
- 39. Khan M, Husain A. Syntheses and reactions of some new 2arylidene-4-(biphenyl-4-yl)-but-3-en-4-olides with a study of their biological activity. Die Pharm 2002;57:448–52.
- 40. Abouzid K, Bekhit SA. Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity. Bioorg Med Chem 2008;16:5547–56.
- 41. Khan M, Husain A. Syntheses and reactions of some new 2arylidene-4-(biphenyl-4-yl)-but-3-en-4-olides with a study of their biological activity. Die Pharm 2002;57:448–52.
- 42. Grover J, Bhatt N, Kumar V, Patel NK, et al. 5-diaryl-1, 3, 4oxadiazoles as selective cox-2 inhibitors and anti-inflammatory agents. RSC Adv 2015;5:45535–44.
- 43. Akhter M, Akhter N, Alam M, et al. Synthesis and biological evaluation of 2,5-disubstituted 1,3,4-oxadiazole derivatives

with both COX and LOX inhibitory activity. J Enzyme Inhib Med Chem 2011;26:767–76.

- 44. Mohamed MS, Mostafa AG, El-hameed RHA. Evaluation of the anti-inflammatory activity of novel synthesized pyrrole, pyrrolopyrimidine and spiropyrrolopyrimidine derivatives. Pharmacophore 2012;3:44–54.
- 45. Mohamed MS, Kamel R, Abd El-hameed RH. Evaluation of the anti-inflammatory activity of some pyrrolo [2, 3-d] pyrimidine derivatives. Med Chem Res 2013;22:2244–52.
- 46. Said Fatahala S, Hasabelnaby S, Goudah A, et al. Pyrrole and fused pyrrole compounds with bioactivity against inflammatory mediators. Molecules 2017;22:461.
- Ahmed Youssef S, Ibrahim Abd El-Mogoud A, Moneer Abdu Ibrahim S, et al. Synthesis and reactions of 2-[α-(3, 4-disubstituted phenacyl)-p-substituted styryl]-4h-3, 1-benzoxazin-4ones. Chin J Chem 2010;14:437–46.
- 48. Abd Alla MM, Soliman EA, Osman MW. Cheminform abstract: reactions of some arylidenefuranones. Chem Inform 1980;11. doi:10.1002/chin.198029210
- 49. Hashem Al, Abou-Elmagd WS, Abdalaziz A. Synthesis and reactions of some 2 (3h) and 2 (5h) furanone derivatives: a comparative study. Eur Chem Bull 2014;3:1064–8.
- 50. Hariram Nile S, Won Park S. Optimized methods for in vitro and in vivo anti-inflammatory assays and its applications in herbal and synthetic drug analysis. Mini Rev Med Chem 2013;13:95–100.
- 51. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107:7–11.
- 52. Burda S, Oleszek W. Antioxidant and antiradical activities of flavonoids. J Agric Food Chem 2001;49:2774–9.
- 53. Rao GH. Physiology of blood platelet activation. Indian J Physiol Pharmacol 1993;37:263.

- 54. Chintakunta VK, Akella V, Vedula MS, et al. 3-o-substituted benzyl pyridazinone derivatives as cox inhibitors. Eur J Med Chem 2002;37:339–347.
- 55. Li CS, Brideau C, Chan CC, Savoie C, et al. Pyridazinones as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 2003;13:597–600.
- 56. Koopaei MN, Assarzadeh MJ, Almasirad A, et al. Synthesis and analgesic activity of novel hydrazide and hydrazine derivatives. Iran J Pharm Res 2013;12:721.
- 57. Sui Z, Guan J, Ferro MP, et al. 1,3-Diarylcycloalkanopyrazoles and diphenyl hydrazides as selective inhibitors of cyclooxy-genase-2. Bioorg Med Chem Lett 2000;10:601–604.
- 58. Hamberg M, Samuelsson B. On the mechanism of the biosynthesis of prostaglandins e-1 and f-1-alpha. J Biol Chem 1967;242:5336–5343.
- 59. Yamamoto S. Mammalian lipoxygenases: molecular structures and functions. Biochim Biophys Acta 1992;1128: 117–131.
- Chowdhury MA, Abdellatif KR, Dong Y, et al. Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorg Med Chem Lett 2008;18: 6138–6141.
- 61. Özadalı K, Özkanlı F, Jain S, et al. Synthesis and biological evaluation of isoxazolo[4,5-d]pyridazin-4-(5H)-one analogues as potent anti-inflammatory agents . Bioorg Med Chem 2012;20:2912–2922.
- 62. Miao Y, Zhao S, Gao Y, et al. Curcumin pretreatment attenuates inflammation and mitochondrial dysfunction in experimental stroke: the possible role of sirt1 signaling. Brain Res Bull 2016;121:9–15.